Group 1 - Evommune, a biotech company focused on therapies for chronic inflammatory diseases, announced its IPO terms, aiming to raise $150 million by offering 9.4 million shares at a price range of $15 to $17 [1] - The company's lead candidate, EVO756, is a potent and selective MRGPRX2 oral small molecule antagonist for chronic spontaneous urticaria (CSU) and atopic dermatitis (AD), currently in a Phase 2b trial with results expected in the second half of 2026 [1] - Evommune's second candidate, EV0301, is a long-acting fusion protein for treating atopic dermatitis (AD) and ulcerative colitis (UC), with plans to initiate a Phase 2 trial for moderate to severe UC patients in 2026 [1] Group 2 - Founded in 2020, Evommune reported revenue of $3 million for the 12 months ending June 30, 2025, and plans to list on the New York Stock Exchange under the ticker "EVMN" [2] - The company has appointed Morgan Stanley, Leerink Partners, Evercore ISI, and Cantor Fitzgerald as joint book-running managers for the IPO, with the final pricing expected during the week of November 3, 2025 [2]

He also leads the investing group IPO Edge , which offers actionable information on growth stocks through first-look IPO filings, previews on upcoming IPOs, an IPO calendar for tracking what’s on the horizon, a database of U.S. IPOs, and a guide to IPO investing to walk you through the entire IPO lifecycle - from filing to listing to quiet period and lockup expiration dates.Analyst’s Disclosure:I/we have no stock, option or similar derivative position in any of the companies mentioned, and no plans to initi ...

Core Insights - The U.S. IPO market remains active despite government shutdown, with 6 traditional IPOs and 2 SPACs launched this week, alongside 13 companies filing for initial public offerings [1][12]. Group 1: IPO Activity - Alliance Laundry Holdings (ALH) raised $826 million, pricing at the upper limit of its range, achieving a market cap of $4.5 billion, and saw a 14% stock price increase [1]. - Phoenix Education Partners (PXED) raised $136 million, pricing at the midpoint of its range, with a market cap of $1.3 billion and a 13% stock price increase [1]. - Ping An Good Doctor (POM) raised $20 million, pricing at the lower limit of its range, with a market cap of $474 million and a 9% stock price increase [2]. - One and One Green Tech (YDDL) raised $10 million, pricing at the midpoint of its range, achieving a market cap of $27 million and a significant 31% stock price increase [2]. - Leifras (LFS) raised $5 million, pricing at the lower limit of its range, with a market cap of $10.5 million, but experienced a 5% stock price decline [2]. - Turn Therapeutics (TTRX) debuted via direct listing at $10, but saw a 26% decline in stock price [3]. Group 2: SPAC Activity - Two SPACs completed their listings: GigCapital8 (GIWWU) raised $220 million and Lake Superior Acquisition (LKSPU) raised $100 million, focusing on energy, social media, and consumer goods [4]. - Five SPACs filed for IPOs, including Xsolla SPAC 1 (XSOLU.RC) and Alussa Energy Acquisition II (ALUBU), both aiming to raise $250 million [8][10]. Group 3: Upcoming IPOs and Market Trends - 13 companies filed for IPOs, including BillionToOne (BLLN), Evommune (EVMN), and Central Bancompany (CBC), each planning to raise $100 million [6]. - The SEC issued new guidelines allowing companies to announce pricing ranges and set final pricing above the range, which may encourage more companies to proceed with listings amid the government shutdown [12].